View all trials
Are you a member? Sign in above to view additional information
  • Study title
    St. Jude Eliot: Phase 1 Evaluation Of Ly2606368, A Molecularly Targeted Chk1/2 Inhibitor Therapy, In Combination With Cyclophosphamide Or Gemcitabine For Children And Adolescents With Refractory Or Recurrent Group 3/Group 4 Or Shh Medulloblastoma Brain Tumors.
  • Protocol ID
    SJELIOT
  • Disease
    Disease Type Disease Subtype
    Brain and Spinal Tumours
    Medulloblastoma/PNET
  • Eligibility criteria
  • Study Status
    Open
  • Location(s)
  • Phase
    Phase 1
  • Study type
    Treatment
  • Diagnosis stage
    Relapse/refractory
  • Study open date
    02/10/2019
  • Study close date
    31/12/2022
  • Study chair
    Dr Nick Gottardo
  • Sponsor
    St Jude
Back to search results